JP2023519640A5 - - Google Patents
Info
- Publication number
- JP2023519640A5 JP2023519640A5 JP2022572258A JP2022572258A JP2023519640A5 JP 2023519640 A5 JP2023519640 A5 JP 2023519640A5 JP 2022572258 A JP2022572258 A JP 2022572258A JP 2022572258 A JP2022572258 A JP 2022572258A JP 2023519640 A5 JP2023519640 A5 JP 2023519640A5
- Authority
- JP
- Japan
- Prior art keywords
- cov
- sars
- coronavirus
- polynucleotide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966750P | 2020-01-28 | 2020-01-28 | |
| US62/966,750 | 2020-01-28 | ||
| US202063048942P | 2020-07-07 | 2020-07-07 | |
| US63/048,942 | 2020-07-07 | ||
| US202063079337P | 2020-09-16 | 2020-09-16 | |
| US63/079,337 | 2020-09-16 | ||
| US202063079853P | 2020-09-17 | 2020-09-17 | |
| US63/079,853 | 2020-09-17 | ||
| PCT/US2021/015246 WO2021154828A1 (en) | 2020-01-28 | 2021-01-27 | DEOPTIMIZED SARS-CoV-2 AND METHODS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519640A JP2023519640A (ja) | 2023-05-11 |
| JP2023519640A5 true JP2023519640A5 (enExample) | 2024-02-06 |
Family
ID=77078567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022572258A Pending JP2023519640A (ja) | 2020-01-28 | 2021-01-27 | 脱最適化されたＳＡＲＳ－ＣｏＶ－２ならびにその方法および使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230117167A1 (enExample) |
| EP (1) | EP4096712A4 (enExample) |
| JP (1) | JP2023519640A (enExample) |
| KR (1) | KR20220132588A (enExample) |
| CN (1) | CN115427073A (enExample) |
| AU (1) | AU2021213121A1 (enExample) |
| BR (1) | BR112022014700A2 (enExample) |
| CA (1) | CA3168100A1 (enExample) |
| CL (1) | CL2022002030A1 (enExample) |
| CO (1) | CO2022010743A2 (enExample) |
| IL (1) | IL295112A (enExample) |
| MX (1) | MX2022009099A (enExample) |
| PE (1) | PE20230166A1 (enExample) |
| PH (1) | PH12022551788A1 (enExample) |
| SA (1) | SA522433428B1 (enExample) |
| TW (1) | TW202144570A (enExample) |
| WO (1) | WO2021154828A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11241493B2 (en) | 2020-02-04 | 2022-02-08 | Curevac Ag | Coronavirus vaccine |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| MX2022009688A (es) * | 2020-02-07 | 2022-12-15 | Rnaimmune Inc | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. |
| WO2021177773A2 (ko) * | 2020-03-06 | 2021-09-10 | (주)지노믹트리 | Sars-cov-2 진단용 조성물, 키트 및 이를 이용한 sars-cov-2의 진단방법 |
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2022011428A1 (en) * | 2020-07-16 | 2022-01-20 | Griffith University | Live-attenuated virus vaccine |
| MX2023007574A (es) | 2020-12-22 | 2023-09-29 | CureVac SE | "vacuna de arn contra variantes de sars-cov-2. |
| TW202328166A (zh) | 2021-08-11 | 2023-07-16 | 美商達冕生物有限公司 | 針對新型冠狀病毒感染之ｍＲＮＡ疫苗之組成物及方法 |
| CN115704013A (zh) * | 2021-08-13 | 2023-02-17 | 北京化工大学 | 一种冠状病毒致弱突变株及其制备方法和应用 |
| US20250057939A1 (en) | 2021-09-08 | 2025-02-20 | Serum Institute Of India Private Limited | Freeze-dried viral combination vaccine compositions and process for preparation thereof |
| US20250295756A1 (en) * | 2022-01-20 | 2025-09-25 | Freie Universität Berlin | Live attenuated sars-cov-2 and a vaccine made thereof |
| KR20240163164A (ko) * | 2022-03-28 | 2024-11-18 | 유니버시태트 베른 | 원-투-스톱(One-to-stop) 약독화된 SARS-CoV-2 바이러스 |
| KR20250060275A (ko) | 2022-09-05 | 2025-05-07 | 프라이 유니베르시탯 베를린 | 살아있는 약독화된 SARS-CoV-2 및 이의 제조 백신 |
| EP4331602A1 (en) * | 2022-09-05 | 2024-03-06 | Freie Universität Berlin | A live attenuated sars-cov-2 and a vaccine made thereof |
| JP2025534031A (ja) * | 2022-10-12 | 2025-10-09 | ウニヴェルズィテート ベルン | ワントゥーストップ（ｏｎｅ－ｔｏ－ｓｔｏｐ）弱毒化ＳＡＲＳ－ＣｏＶ－２ウイルスによる治療 |
| WO2024089638A1 (en) | 2022-10-28 | 2024-05-02 | Glaxosmithkline Biologicals Sa | Nucleic acid based vaccine |
| WO2024097259A1 (en) | 2022-11-01 | 2024-05-10 | RNAimmune, Inc. | Composition and methods for mrna vaccines against novel omicron coronavirus infections |
| WO2025081050A1 (en) * | 2023-10-13 | 2025-04-17 | Duke University | Coronavirus stem helix and fusion peptide nanoparticle vaccines |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7339051B2 (en) * | 2003-04-28 | 2008-03-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (SARS) |
| EP2808384B1 (en) * | 2004-10-08 | 2017-12-06 | The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
| PL2139515T5 (pl) * | 2007-03-30 | 2024-04-08 | The Research Foundation Of The State University Of New York | Atenuowane wirusy przydatne w szczepionkach |
| US20120269849A1 (en) * | 2009-10-09 | 2012-10-25 | Eckard Wimmer | Attenuated influenza viruses and vaccines |
| CN104072592B (zh) * | 2013-03-26 | 2016-12-28 | 复旦大学 | 对新型冠状病毒HCoV-EMC 2012感染具有抑制作用的多肽及其应用 |
| KR20180085802A (ko) * | 2015-12-11 | 2018-07-27 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Ns1 및 ns2 유전자 이동을 포함하는 재조합 rsv 균주 |
| CN110506060B (zh) * | 2017-03-30 | 2024-05-07 | 昆士兰大学 | 嵌合分子及其用途 |
| US20200299651A1 (en) * | 2017-10-16 | 2020-09-24 | Glaxosmithkline Biologicals Sa | Simian adenoviral vectors with two expression cassettes |
-
2021
- 2021-01-27 CN CN202180024216.XA patent/CN115427073A/zh active Pending
- 2021-01-27 WO PCT/US2021/015246 patent/WO2021154828A1/en not_active Ceased
- 2021-01-27 EP EP21747780.1A patent/EP4096712A4/en active Pending
- 2021-01-27 AU AU2021213121A patent/AU2021213121A1/en not_active Abandoned
- 2021-01-27 CA CA3168100A patent/CA3168100A1/en active Pending
- 2021-01-27 IL IL295112A patent/IL295112A/en unknown
- 2021-01-27 BR BR112022014700A patent/BR112022014700A2/pt unknown
- 2021-01-27 KR KR1020227029265A patent/KR20220132588A/ko active Pending
- 2021-01-27 PH PH1/2022/551788A patent/PH12022551788A1/en unknown
- 2021-01-27 TW TW110103098A patent/TW202144570A/zh unknown
- 2021-01-27 MX MX2022009099A patent/MX2022009099A/es unknown
- 2021-01-27 US US17/794,862 patent/US20230117167A1/en active Pending
- 2021-01-27 PE PE2022001498A patent/PE20230166A1/es unknown
- 2021-01-27 JP JP2022572258A patent/JP2023519640A/ja active Pending
-
2022
- 2022-07-27 SA SA522433428A patent/SA522433428B1/ar unknown
- 2022-07-28 CL CL2022002030A patent/CL2022002030A1/es unknown
- 2022-07-29 CO CONC2022/0010743A patent/CO2022010743A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512519A5 (enExample) | ||
| RU2233333C2 (ru) | Вирусные векторы и их применение в генной терапии | |
| KR920007439B1 (ko) | 하이브리드 인간 백혈구 인터페론 | |
| EP3821906A1 (en) | Vaccine against rsv comprising modified f polypeptide | |
| JP2002503477A5 (enExample) | ||
| JP2025184979A5 (enExample) | ||
| RU2012107671A (ru) | Композиция для лечения инфекции вирусом гепатита в | |
| JP2014527404A5 (enExample) | ||
| JP2013501038A5 (enExample) | ||
| US5521070A (en) | DNA sequence coding for human factor IX or a similar protein, expression vector, transformed cells, method for preparing factor IX and corresponding products obtained | |
| EP4479436A1 (en) | Mutant cytidine deaminases with improved editing precision | |
| JP2022530833A5 (enExample) | ||
| WO1998036779A3 (en) | System for the in vivo delivery and expression of heterologous genes in the bone marrow | |
| JP2002533124A5 (enExample) | ||
| JP2022513459A5 (enExample) | ||
| Seeger et al. | Identification of a signal necessary for initiation of reverse transcription of the hepadnavirus genome | |
| FI3850089T3 (fi) | Polynukleotidejä | |
| JP2018537089A5 (enExample) | ||
| JP2025508676A5 (enExample) | ||
| CA2385325A1 (en) | Chlamydia antigens and corresponding dna fragments and uses thereof | |
| JP2022513718A5 (enExample) | ||
| WO2004048402B1 (en) | A hepatitis c virus codon optimized non-structural ns3/4a fusion gene | |
| AU2021301381A1 (en) | Compositions for genome editing and methods of use thereof | |
| JP2023536570A5 (enExample) | ||
| US20250026793A1 (en) | Chimeric betacoronavirus spike polypeptides |